Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy

URN:NBN:SI:doc-5E1FZ0DF2022Beniak, JurajBorštnar, SimonaGal-Yam, Einav NiliKudela, PavolŁacko, AleksandraPalacova, MarketaPapazisis, KonstantinosRubovszky, GáborTimcheva, Constantadocuments/doc/5/URN_NBN_SI_doc-5E1FZ0DF_001.pdfdocuments/doc/5/URN_NBN_SI_doc-5E1FZ0DF_001.txt256articlestr. 238-24710.2478/raon-2022-00201081848351318-2099URN:NBN:SI:doc-5E1FZ0DFengAssociation of Radiology and OncologyRadiology and oncology (Ljubljana)BYadvanced breast cancerCDK4/6 inhibitorHER2-HR+inhibitor CDK4/6napredovali rak dojkeribociclibRibociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapysubgroup safety analysis from the phase 3b CompLEEment-1 trial